[A review of immune-related adverse events associated with immunotherapy].

Fang, Y; Yu, Y; Wu, D W; Fang, H; Huang, H Y; Wang, S H; Yu, A Q; Sun, C; Bai, Y; Wang, H; Li, N

Fang, Y; Yu, Y; Wu, D W; Fang, H; Huang, H Y; Wang, S H; Yu, A Q; Sun, C; Bai, Y; Wang, H; Li, N.

Affiliation

Fang Y; GCP center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Zhonghua Zhong Liu Za Zhi ; 42(1): 17-21, 2020 Jan 23.

Article in Zh | MEDLINE | ID: mdl-32023764

Subject(s)

Immunotherapy; Neoplasms; China; Humans; Incidence; Neoplasms/therapy

Key words

Immune checkpoint inhibitor; Immune related adverse events; PD-1 inhibitor; PD-L1 inhibitor

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunotherapy / Neoplasms Type of study: Guideline / Incidence_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Asia Language: Zh Journal: Zhonghua Zhong Liu Za Zhi Year: 2020 Document type: Article

Fulltext

XML

PubMed Links

Search on Google